Cargando…
Immune monitoring technology primer
BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The p...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615874/ https://www.ncbi.nlm.nih.gov/pubmed/26500774 http://dx.doi.org/10.1186/s40425-015-0086-9 |
_version_ | 1782396525617348608 |
---|---|
author | Dobbin, Kevin K. |
author_facet | Dobbin, Kevin K. |
author_sort | Dobbin, Kevin K. |
collection | PubMed |
description | BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The process of clinically validating a predictive biomarker is reviewed. Validation of a predictive biomarker requires quantifying the strength of a statistical interaction between marker and a treatment. Different study designs are considered. CONCLUSIONS: Clinical validation of immunology biomarkers can be demanding both in terms of time and resources, and careful planning and study design are critical. |
format | Online Article Text |
id | pubmed-4615874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46158742015-10-23 Immune monitoring technology primer Dobbin, Kevin K. J Immunother Cancer Short Report BACKGROUND: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. FINDINGS: The process of clinically validating a predictive biomarker is reviewed. Validation of a predictive biomarker requires quantifying the strength of a statistical interaction between marker and a treatment. Different study designs are considered. CONCLUSIONS: Clinical validation of immunology biomarkers can be demanding both in terms of time and resources, and careful planning and study design are critical. BioMed Central 2015-10-20 /pmc/articles/PMC4615874/ /pubmed/26500774 http://dx.doi.org/10.1186/s40425-015-0086-9 Text en © Dobbin. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Short Report Dobbin, Kevin K. Immune monitoring technology primer |
title | Immune monitoring technology primer |
title_full | Immune monitoring technology primer |
title_fullStr | Immune monitoring technology primer |
title_full_unstemmed | Immune monitoring technology primer |
title_short | Immune monitoring technology primer |
title_sort | immune monitoring technology primer |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615874/ https://www.ncbi.nlm.nih.gov/pubmed/26500774 http://dx.doi.org/10.1186/s40425-015-0086-9 |
work_keys_str_mv | AT dobbinkevink immunemonitoringtechnologyprimer |